[Serum prolactin in obese subjects with glucose intolerance before and after treatment with phenformin].
10 obese subjects with latent glucose-intolerance we studied before and after a "short term" treatment with an oral antidiabetic drug, phenformina (100 mg/day for 14 days). The parameters we evaluated, were: basal IRI, C-peptide immunoreactive (IRCP), IRCP/IRI ratio, areas elicited by values of IRI after oral glucose tolerance test (OGTT), basal H-Prl, before and after the phenformin (F) treatment. Our data show that F decreases the basal IRI values but not IRCP values, so the IRCP/IRI ratio is significantly higher. No difference is found in the basal H-Prl values.
D000328:Adult; D002096:C-Peptide / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D009765:Obesity; D010629:Phenformin / Q000627:therapeutic use*; D011236:Prediabetic State / Q000097:blood*; D011388:Prolactin / Q000097:blood*
D002096:C-Peptide; D007328:Insulin; D011388:Prolactin; D010629:Phenformin
Comportamento della prolattinemia in soggetti obesi con intolleranza ai carboidrati prima e dopo trattamento con fenformina.